Castle Biosciences (CSTL) Total Debt (2018 - 2026)

Castle Biosciences has reported Total Debt for 7 years, with the latest figure at $13.0 million in Q2 2026.

• Quarterly Total Debt rose 8.41% year-over-year to $13.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $13.0 million (up 8.41% YoY) and the FY2025 annual result came in at $10.5 million, up 1.68% from the prior year.
• Total Debt improved to $13.0 million in Q2 2026 per CSTL's latest filing, from $11.7 million in the prior quarter.
• Over five years, Total Debt peaked at $20.8 million in Q1 2022 and troughed at $10.0 million in Q1 2024.
• A 4-year average of $11.8 million and a median of $10.5 million in 2025 frame the typical range for Total Debt.
• The widest YoY moves for Total Debt: up 19.74% in 2025, down 0.34% in 2025.
• Over 4 years, Total Debt stood at $20.8 million in 2022, then slumped by 50.59% to $10.3 million in 2024, then gained by 1.68% to $10.5 million in 2025, then rose by 24.04% to $13.0 million in 2026.
• According to Business Quant data, Total Debt over the past three periods registered $13.0 million, $11.7 million, and $10.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.